Clinical characteristics predicting early clinical failure after 72 h of antibiotic treatment in women with community-onset acute
pyelonephritis: a prospective multicentre study
- Author(s)
- S.-H. Wie; M. Ki; J. Kim; Y. K. Cho; S.-K. Lim; J. S. Lee; K. T. Kwon; H. Lee; H. J. Cheong; D. W. Park; S. Y. Ryu; M.-H. Chung; H. Pai
- Keimyung Author(s)
- Ryu, Seong Yeol
- Department
- Dept. of Internal Medicine (내과학)
- Journal Title
- Clinical Microbiology and Infection
- Issued Date
- 2014
- Volume
- 20
- Issue
- 10
- Abstract
- In patients with community-onset acute pyelonephritis (CO-APN), assessing the risk factors for poor clinical response after 72 h of
antibiotic treatment (early clinical failure) is important. The objectives of this study were to define those risk factors, and to assess whether
early clinical failure influences mortality and treatment outcomes. We prospectively collected the clinical and microbiological data of women
with CO-APN in South Korea from March 2010 to February 2012. The numbers of cases in the early clinical success and early clinical failure
groups were 840 (79.1%) and 222 (20.9%), respectively. Final clinical failure and mortality were higher in the early clinical failure group than
in the early clinical success group (14.9% vs 2.3%, p <0.001; 6.8% vs 0.1%, p 0.001, respectively). In a multiple logistic regression model, the
risk factors for early clinical failure among the total 1062 patients were diabetes mellitus (OR 1.5; 95% CI 1.1–2.1), chronic liver diseases
(OR 3.3; 95% CI 1.6–6.7), malignancy (OR 2.2; 95% CI 1.1–4.4), Pitt score ≥2 (OR 2.5; 95% CI 1.6–3.8), presence of azotaemia (OR 1.8; 95%
CI 1.2–2.7), white blood cell count ≥20 000/mm3 (OR 2.5; 95% CI 1.6–4.0), serum C-reactive protein level ≥20 mg/dL (OR 1.7; 95% CI 1.2–
2.4), and history of antibiotic usage within the previous year (OR 1.5; 95% CI 1.1–2.2). Analysing the subgroup of 743 patients with CO-APN
due to Enterobacteriaceae, fluoroquinolone resistance of the uropathogen was another factor associated with early clinical failure (OR 1.7;
95% CI 1.1–2.5). Simple variables of underlying diseases, previous antibiotic usage and initial laboratory test outcomes can be used to decide
on the direction of treatment in CO-APN.
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.